Trial Profile
Observational research to decide optimal dose of Afatinib in patients with primary lung adenocarcinoma harbouring the sensitive mutation of epidermal growth factor receptor (EGFR) by pharmacokinetic analyses
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions
- 28 May 2022 Planned End Date changed from 31 Jul 2022 to 31 Mar 2022.
- 28 May 2022 Status changed from recruiting to discontinued.
- 30 Oct 2018 Status changed from not yet recruiting to recruiting.